Leerink Partnrs Brokers Lower Earnings Estimates for Arvinas

Arvinas, Inc. (NASDAQ:ARVN - Free Report) - Leerink Partnrs lowered their FY2025 earnings per share (EPS) estimates for shares of Arvinas in a research report issued on Tuesday, November 19th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings per share of ($2.98) for the year, down from their previous forecast of ($2.85). The consensus estimate for Arvinas' current full-year earnings is ($3.32) per share. Leerink Partnrs also issued estimates for Arvinas' FY2026 earnings at ($3.64) EPS and FY2027 earnings at $1.38 EPS.

A number of other research firms have also recently commented on ARVN. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arvinas in a research report on Monday, September 9th. BMO Capital Markets cut their price objective on shares of Arvinas from $90.00 to $88.00 and set an "outperform" rating for the company in a research report on Wednesday. Stephens assumed coverage on shares of Arvinas in a research note on Monday. They set an "overweight" rating and a $55.00 price objective on the stock. Wedbush reaffirmed an "outperform" rating and issued a $57.00 target price on shares of Arvinas in a research note on Tuesday, July 30th. Finally, Barclays reduced their price target on Arvinas from $60.00 to $48.00 and set an "overweight" rating on the stock in a research note on Wednesday, July 31st. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $61.08.

Arvinas Stock Performance

ARVN stock traded up $0.75 on Friday, reaching $25.86. The company had a trading volume of 1,060,227 shares, compared to its average volume of 720,106. Arvinas has a 1 year low of $21.17 and a 1 year high of $53.08. The company's fifty day moving average is $25.63 and its 200 day moving average is $27.05. The company has a market cap of $1.78 billion, a P/E ratio of -5.48 and a beta of 1.96.

Arvinas (NASDAQ:ARVN - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported ($0.68) EPS for the quarter, beating analysts' consensus estimates of ($0.88) by $0.20. The business had revenue of $102.40 million during the quarter, compared to analyst estimates of $60.56 million. Arvinas's revenue was up 196.0% on a year-over-year basis. During the same period in the previous year, the company posted ($1.18) earnings per share.

Institutional Investors Weigh In On Arvinas

Several institutional investors and hedge funds have recently modified their holdings of the stock. M&T Bank Corp boosted its stake in shares of Arvinas by 53.5% during the 3rd quarter. M&T Bank Corp now owns 27,137 shares of the company's stock valued at $669,000 after buying an additional 9,462 shares during the last quarter. Barclays PLC raised its stake in Arvinas by 198.9% during the third quarter. Barclays PLC now owns 121,699 shares of the company's stock worth $2,998,000 after acquiring an additional 80,984 shares during the period. Nomura Asset Management Co. Ltd. lifted its holdings in shares of Arvinas by 36.3% in the 3rd quarter. Nomura Asset Management Co. Ltd. now owns 90,870 shares of the company's stock worth $2,238,000 after purchasing an additional 24,223 shares during the last quarter. XTX Topco Ltd bought a new position in Arvinas during the 3rd quarter worth $453,000. Finally, Zacks Investment Management increased its position in Arvinas by 9.8% in the third quarter. Zacks Investment Management now owns 89,827 shares of the company's stock worth $2,212,000 after buying an additional 8,029 shares during the period. Hedge funds and other institutional investors own 95.19% of the company's stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.